Caution should be exercised when prescribing or uptitrating ranolazine to patients in whom an increased exposure is expected: • Concomitant administration of moderate CYP3A4 inhibitors (see sections 4.2 and 4.5). • Concomitant administration of P-gp inhibitors (see sections 4.2 and 4.5). • Mild hepatic impairment (see sections 4.2 and 5.2). • Mild to moderate renal impairment (creatinine clearance 30– 80 ml/ min) (see sections 4.2, 4.8, and 5.2). • Elderly (see sections 4.2, 4.8, and 5.2). • Patients with low weight (≤ 60 kg) (see sections 4.2, 4.8, and 5.2). • Patients with moderate to severe CHF (NYHA Class III– IV) (see sections 4.2 and 5.2).